Search
Prenetics Global Ltd
PREAdd to Watchlist
16.930USD
-0.960-5.37%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
287.82MMarket Cap
LossP/E TTM
More Details of Prenetics Global Ltd Company
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Prenetics Global Ltd Info
Ticker SymbolPRE
Company namePrenetics Global Ltd
IPO dateJul 06, 2021
CEOKwok (Samantha)
Number of employees285
Security typeOrdinary Share
Fiscal year-endJul 06
AddressUnit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay
City
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryHong Kong
Postal code- -
Phone85222109588
Websitehttps://ir.prenetics.com/
Ticker SymbolPRE
IPO dateJul 06, 2021
CEOKwok (Samantha)
Company Executives of Prenetics Global Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--
Ms. Wing Kwan (Winnie) Chiu
Ms. Wing Kwan (Winnie) Chiu
Independent Director
Independent Director
--
--
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Hoi Chun (Stephen) Lo
Mr. Hoi Chun (Stephen) Lo
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Yung Ho (Peter) Wong
Dr. Yung Ho (Peter) Wong
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Joel Neoh
Mr. Joel Neoh
Chief Consumer Officer, Chief Executive Officer of CircleDNA
Chief Consumer Officer, Chief Executive Officer of CircleDNA
--
--
Ms. Kathryn Henry
Ms. Kathryn Henry
Independent Director
Independent Director
--
--
Mr. David Vanderveen
Mr. David Vanderveen
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--
Ms. Wing Kwan (Winnie) Chiu
Ms. Wing Kwan (Winnie) Chiu
Independent Director
Independent Director
--
--
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Hoi Chun (Stephen) Lo
Mr. Hoi Chun (Stephen) Lo
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
FAQs
Who are the top five shareholders of Prenetics Global Ltd?
The top five shareholders of Prenetics Global Ltd are: Mr. Sheng Wu (Danny) Yeung
How many institutions hold shares of Prenetics Global Ltd (PRE)?
As of 2026Q1, 46 institutions hold shares of Prenetics Global Ltd, with a combined market value of approximately 1.76M, accounting for 11.33% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -778478.00.